Epilepsies, Partial: Clinical Trials

328 trials for Epilepsies, Partial, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

178 completed, 47 recruiting, 42 unknown, 31 terminated. 80 Not applicable, 73 Phase 3, 49 Phase 2, 38 Phase 4, 14 Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable80Completed 27, Recruiting 20, Unknown 19, Terminated 5, Active not recruiting 3, Withdrawn 3, Not yet recruiting 2, Enrolling by invitation 1
Phase 373Completed 54, Terminated 10, Active not recruiting 3, Recruiting 3, Withdrawn 2, Enrolling by invitation 1
Phase 249Completed 25, Recruiting 9, Terminated 7, Active not recruiting 3, Withdrawn 3, Enrolling by invitation 1, Unknown 1
Phase 438Completed 22, Terminated 7, Unknown 5, Recruiting 2, Not yet recruiting 1, Withdrawn 1
Phase 114Completed 8, Terminated 2, Unknown 2, Recruiting 1, Withdrawn 1
Early Phase 13Recruiting 2, Unknown 1

Follow Epilepsies, Partial: new trials by email Literature Review of Epilepsies, Partial trials Research Report on Epilepsies, Partial

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Accelerated iTBS for Depression and Suicidality
Accelerated Intermittent Theta Burst (aiTBS), Electroconvulsive therapy (ECT) - Major Depressive Disorder, Suicide
Not applicableNot yet recruitingUniversity of Iowa502026-12-012025-05-20
Studying Heart Rhythms With a Wearable Sensor to Detect and Predict Seizures in People With Epilepsy
Textile-based wearable electrocardiography - Epilepsy, Temporal Lobe, Drug Resistant Epilepsy
Not yet recruitingAcibadem University402026-10-152026-09-23
Overnight TI in TLE
Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi - Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy
Not applicableRecruitingDuke University202026-10-152026-10-16
RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study
NeuroPace RNS System - Focal Epilepsy, Drug-resistant Focal Epilepsy
Enrolling by invitationNeuroPace1002026-09-142026-09-16
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
RAP-219, Placebo - Focal Seizure, Epilepsy
Phase 3RecruitingRapport Therapeutics Inc.3122026-09-012026-10-15
High-density Flexible μECoG for Epilepsy Surgery - A Single-Arm ECT
Using High-density Flexible microElectrocorticography for intraoperative monitoring - Focal Epilepsy, Intraoperative Monitoring
Not applicableRecruitingBeijing Tiantan Hospital852026-09-012026-08-13
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
Zonisamide Oral Product - Seizures, Seizures, Focal
Phase 4Not yet recruitingAzurity Pharmaceuticals402026-09-012026-09-15
Prognosis of Epilepsy With Post-traumatic Stress Disorder and Surgery
Baseline PTSD status, Psychiatric questionnaires - Epilepsies, Focal, Drug Restistant Epilepsie
Not yet recruitingAssistance Publique Hopitaux De Marseille422026-09-012026-07-22
Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG Monitoring
Probenecid, Placebo - Focal Epilepsy
Phase 2RecruitingFondation Ophtalmologique Adolphe de Rothschild6002026-08-242026-10-05
A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds
Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds - Partial Epilepsy
Phase 3RecruitingOno Pharmaceutical Co., Ltd.202026-06-102026-10-09
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
RAP-219, Placebo - Focal Seizure, Epilepsy
Phase 3RecruitingRapport Therapeutics Inc.3332026-06-052026-10-21
MRI Volumetry and Diffusion Tensor Imaging in Temporal Lobe Epilepsy
MRI - Temporal Lobe Epilepsy (TLE)
Not yet recruitingAssiut University782026-04-012026-02-03
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks - Focal Epilepsy
Phase 3Active not recruitingPraxis Precision Medicines3002026-01-292026-08-03
Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables
UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM) - Focal Epilepsy, Generalized Seizure
Early Phase 1RecruitingMayo Clinic122026-01-202026-09-25
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RAP-219 - Focal Epilepsy, Epilepsy
Phase 2RecruitingRapport Therapeutics Inc.302025-12-152026-01-23
Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures
Eslicarbazepine acetate - Focal-Onset Seizures
RecruitingKing Edward Medical University15002025-12-022026-09-09
Thalamic Recordings in Children Undergoing SEEG
Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei - Focal Epilepsy
Not applicableRecruitingGreat Ormond Street Hospital for Children NHS Foundation Trust302025-09-012026-02-02
Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
Butylphthalide, Placebo - Focal Epilepsy, Cognitive Impairment
Phase 4RecruitingFirst Affiliated Hospital of Wenzhou Medical University2202025-09-012025-09-25
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
CB03-154 - Focal Epilepsy
Phase 2RecruitingShanghai Zhimeng Biopharma, Inc.1442025-08-142025-11-20
Wearable Epileptic Seizure Prediction and Alert Glasses Based on Neuromorphic Computing
Wearable seizure prediction and alert glasses - Epilepsy, Epileptic Seizures
Not applicableActive not recruitingOman Ministry of Health472025-08-102025-10-07

Showing 20 of 328. Sign in to see all of them.

Narrower conditions

Epilepsy (148)  ·  Seizures (87)  ·  Epilepsy, Temporal Lobe (62)  ·  Drug Resistant Epilepsy (30)  ·  Epilepsy, Rolandic (22)  ·  Epilepsy, Complex Partial (16)  ·  Epilepsy, Generalized (10)  ·  Brain Diseases (9)  ·  Depression (8)  ·  Epilepsy, Frontal Lobe (5)  ·  Epilepsy, Partial, Motor (5)  ·  Anxiety Disorders (4)  ·  Depressive Disorder, Major (4)  ·  Epilepsy, Tonic-Clonic (4)

Broader conditions

Nervous System Diseases (328)  ·  Central Nervous System Diseases (327)  ·  Brain Diseases (319)  ·  Epilepsy (180)  ·  Pathological Conditions, Signs and Symptoms (104)  ·  Neurologic Manifestations (102)  ·  Signs and Symptoms (101)  ·  Epileptic Syndromes (91)  ·  Mental Disorders (20)  ·  Behavior (15)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10)  ·  Behavioral Symptoms (8)  ·  Congenital Abnormalities (6)  ·  Genetic Diseases, Inborn (6)

Interventions

Levetiracetam (23)  ·  Pregabalin (20)  ·  Topiramate (16)  ·  Lacosamide (13)  ·  Oxcarbazepine (10)  ·  eslicarbazepine acetate (9)  ·  Cenobamate (8)  ·  Gabapentin (7)  ·  Lamotrigine (7)  ·  S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (7)  ·  Carbamazepine (5)  ·  ganaxolone (5)  ·  Zonisamide (4)  ·  ezogabine (4)  ·  perampanel (4)

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS) (18)  ·  UCB Pharma (17)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (15)  ·  SK Life Science, Inc. (13)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (12)  ·  Pfizer (8)  ·  Bial - Portela C S.A. (7)  ·  GlaxoSmithKline (7)  ·  Hospices Civils de Lyon (7)  ·  Supernus Pharmaceuticals, Inc. (6)  ·  Marinus Pharmaceuticals (5)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (5)  ·  Fondation Ophtalmologique Adolphe de Rothschild (4)  ·  King's College London (4)  ·  Mayo Clinic (4)

Countries

United States (136)  ·  France (51)  ·  Germany (35)  ·  Poland (26)  ·  Canada (23)  ·  Spain (23)  ·  United Kingdom (23)  ·  Australia (21)  ·  Belgium (20)  ·  China (20)  ·  Italy (20)  ·  Mexico (20)  ·  Hungary (19)  ·  South Korea (19)  ·  Netherlands (17)

Top investigators

William H Theodore, M.D. (5)  ·  Marc Kamin, MD (3)  ·  Daniel Lowenstein, MD (2)  ·  Janet K Johnson, PhD (2)  ·  Liankun Ren, MD (2)  ·  Maciej Gasior, MD, PhD (2)  ·  Project Leader (2)

Results publications

PMID 33338829, PMID 34870321, PMID 19863578, PMID 21095488, PMID 35965432, PMID 10768307, PMID 12552030, PMID 12690085, PMID 17369059, PMID 19001248, PMID 19243423, PMID 19702752, PMID 20041945, PMID 20089937, PMID 20331461, PMID 20462804, PMID 20547106, PMID 21095980, PMID 21140291, PMID 21320109, PMID 21391767, PMID 21673279, PMID 21889410, PMID 22372628, PMID 22396514, PMID 22399764, PMID 22633629, PMID 22708895, PMID 22813235, PMID 23219031, PMID 23223279, PMID 24111974, PMID 24370818, PMID 24415567, PMID 24754318, PMID 24902473, PMID 24962242, PMID 25176152, PMID 25377429, PMID 25461210, PMID 25564232, PMID 25663221, PMID 25684224, PMID 25741734, PMID 25769377, PMID 25854635, PMID 25948717, PMID 26143305, PMID 26399310, PMID 26526971

NIH funding

2014 (6), 2004 (3), 2023 (3), 2009 (2), 2018 (2), 2019 (2), 1UG3NS112826-01 (1), 2005 (1), 2008 (1), 2015 (1), DP1MH116506 (1), K23AT001933 (1), K23NS116110 (1), R01NS047530 (1), R01NS065840 (1)